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Background:  
 
This summary is based on a Cochrane review (Wilkinson & Izmeth, 2016) that 
explores ongoing treatments for depression in older people to prevent relapse 
and recurrence. With population ageing (United Nations, 2017), it is important 
to recognise any idiosyncrasies between depression in older and younger 
individuals, to provide more personalised nursing care. This review focusses 
on the continuation and maintenance phase of care, as whilst many older 
people are treated with antidepressants (Percudani, Fortino, & Petrovich, 
2005), and the short-term effects of this are thought to be good (Katona & 
Livingstone, 2002), we also need to consider how best to sustain good mental 
health after clinical recovery. 
 
Determinants of depression in later life may vary from younger adults (Aziz & 
Steffens, 2013); therefore assessing the effectiveness of interventions, which 
have contrasting mechanisms of action, may warrant differential examination 
for older adults. When considering treatment options with older adults, the 
potential adverse effects of medications and pharmaceutical interactions 
when treating multiple morbidities also requires careful consideration. 
Antidepressant drugs (particularly selective serotonin reuptake inhibitors, 
SSRIs), have for example been associated with increased risk of falling, 
multiple falls, and injurious falls (Kerse et al., 2008). These adverse outcomes 
are important determinants of health in older people, with associated 
morbidities compounding the disability experienced with depression (Xu & 
Rivera Drew, 2018). 
 
Objectives: 
This review aimed to explore the effectiveness of antidepressants and 
psychological therapies, on their own or in combination, for preventing relapse 
and recurrence of depression in older people. 
 
Intervention/Methods:  
This review included randomised trials comparing treatments for people 60 
years or over (any setting), in which some or all of whom were in remission or 
had recovered from depression. Trials including people with bipolar disorder, 
dementia, and other severe mental disorders were excluded. 
 
The review scope included any antidepressant (any dose), and any structured 
psychological therapy (any duration/intensity). Interventions could be 
compared to each other, placebo, or ‘treatment as usual’/waiting list control. 
Studies on electroconvulsive therapy, antipsychotic medication, lithium, or in 
which some therapy recipients were not the older person (e.g. family therapy), 
were excluded. Included trials needed to randomise participants at the 
continuation/maintenance phase of their care. The primary outcomes were 
recurrence of depression and participant drop-outs at one year. 
 
The authors searched (to July 2015) the specialised register of the Cochrane 
Common Mental Disorders Group (covering Medline, Embase, PsychINFO, 
and CENTRAL), clinical trials registries, reference lists, conference abstracts, 
and hand searched four journals. Authors conducted study selection, data 
extraction, and risk of bias assessments independently in duplicate, resolving 
disagreements through discussion. Treatment effects were calculated using 
risk ratios, 95% confidence intervals, and random effects meta-analysis.  
 
Results: 
Seven studies (803 participants; range: 43 to 305 participants) were included. 
There was low quality evidence that antidepressants alone (RR = 0.67, 95% 
CI 0.55 to 0.82; 3 trials, 247 participants), or nortriptyline combined with 
Interpersonal Therapy (RR = 0.42, 95% CI 0.23 to 0.77; 1 trial, 54 
participants) is more beneficial than placebo. There were no differences in 
any of the other active treatment comparisons examined (based on limited 
studies), nor in Interpersonal Therapy alone versus placebo. Data on number 
of drop-outs were sparse, and where present showed no difference between 
treatments. 
 
Conclusions:  
The review authors conclude that the benefits and harms of long-term 
antidepressant continuation for preventing depression recurrence in older 
people are not clear. Nurses should be mindful that although there was a 
beneficial effect for antidepressants at 12 months, and antidepressants 
appeared no more harmful than placebo, the studies contributing these data 
were small, with different populations and variations in medications assessed. 
Data from other treatment comparisons were also too limited to draw firm 
conclusions. The quality of the evidence summarised in this review was 
deemed to be low. Faced with no firm conclusions from the research 
evidence, the most sensible approach for nursing care is to continue as usual 
(following clinical guidelines) until further evidence becomes available. 
 
Implications for Practice:  
The National Institute for Health and Care Excellence (NICE, 2018; further 
update in progress) offers guidance for adults of all ages. For older people, it 
highlights that antidepressants should be prescribed at an age-appropriate 
dose considering general health and concomitant medication interactions, and 
to monitor side effects (Van Damme, Declercq, Lemey, Tandt, & Petrovic, 
2018). The guidance for continuation and maintenance is to encourage 
continued antidepressant use for at least six months for those who have 
benefitted from them, and for two years or more if the individual risks relapse, 
with careful monitoring. NICE (2018) also recommends that those with 
significant risk of relapse or residual symptoms are offered cognitive 
behavioural therapy or mindfulness-based cognitive therapy. Nurses remain 
part of an important shared decision-making process, informing and 
discussing with patients their treatment options, signposting to wider support 
networks as required, to determine the best plans for individuals as part of 
patient-centred care. 
 
References:  
Wilkinson, P., & Izmeth, Z. (2016). Continuation and maintenance treatments 
for depression in older people. Cochrane Database of Systematic Reviews, 9. 
John Wiley & Sons, Ltd. DOI: 10.1002/14651858.CD006727.pub3 
 
 
                                         
 
Aziz, R., & Steffens, D. C. (2013). What Are the Causes of Late-Life 
Depression? Psychiatric Clinics of North America, 36(4), 497–516. 
doi:10.1016/j.psc.2013.08.001. 
 
Katona, C. L., & Livingstone, G. (2002). How well do antidepressants work in 
older people: a systematic review of number needed to treat. Journal of 
Affective Disorders, 69(1-3), 47‐52. 
 
Kerse, N., Flicker, L., Pfaff, J. J., Draper, B., Lautenschlager, N. T., Sim, M., 
Snowdon, J., & Almeida, O.P. (2008). Falls, Depression and Antidepressants 
in Later Life: A Large Primary Care Appraisal. PLOS One, 3(6), 
e2423. https://doi.org/10.1371/journal.pone.0002423 
 
National Institute for Health and Care Excellence. (2018). Depression in 
adults: recognition and management. National Clinical Practice Guideline 90, 
2018. www.nice.org.uk/Guidance/cg90 (accessed 8 August 2018). 
 
Percudani, M. B. C., Fortino, I., & Petrovich, L. (2005). Antidepressant drug 
prescribing among elderly subjects: a population‐based study. International 
Journal of Geriatric Psychiatry, 20(2), 113‐8 
 
United Nations, Department of Economic and Social Affairs, Population 
Division (2017). World Population Prospects: The 2017 Revision, Key 
Findings and Advance Tables. ESA/P/WP/248. 
 
Van Damme, A., Declercq, T., Lemey, L., Tandt, H., & Petrovic, M. (2018). 
Late-life depression: issues for the general practitioner. International Journal 
of General Medicine, 11, 113–120. doi:  10.2147/IJGM.S154876 
 
Xu, D., & Rivera Drew, J. A. (2018). What Doesn’t Kill You Doesn’t Make You 
Stronger: The Long-Term Consequences of Nonfatal Injury for Older 
Adults, The Gerontologist, 58(4), 759–767. doi: 10.1093/geront/gnw252 
